UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents

Pharmacology & therapeutics (Oxford), 2016-08, Vol.164, p.204-225

2016

Volltextzugriff (PDF)

Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy

Journal of medicinal chemistry, 2012-05, Vol.55 (10), p.4527-4538

2012

Volltextzugriff (PDF)

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies

PloS one, 2016-03, Vol.11 (3), p.e0150585-e0150585

2016

Volltextzugriff (PDF)

Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition

Molecular cancer therapeutics, 2019-04, Vol.18 (4), p.856-867

2019

Volltextzugriff (PDF)

Structural and Evolutionary Division of Phosphotyrosine Binding (PTB) Domains

Journal of molecular biology, 2005-01, Vol.345 (1), p.1-20

2005

Volltextzugriff (PDF)

CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis

Human molecular genetics, 2005-09, Vol.14 (17), p.2521-2531

2005

Volltextzugriff (PDF)

Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock

Nature cell biology, 2003-12, Vol.5 (12), p.1104-1110

2003

Volltextzugriff (PDF)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Frontiers in oncology, 2022-05, Vol.12, p.869078-869078

2022

Volltextzugriff (PDF)

Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models

Molecular cancer therapeutics, 2015-02, Vol.14 (2), p.480-490

2015

Volltextzugriff (PDF)

Ablation of MEKK4 Kinase Activity Causes Neurulation and Skeletal Patterning Defects in the Mouse Embryo

Molecular and Cellular Biology, 2005-10, Vol.25 (20), p.8948-8959

2005

Volltextzugriff (PDF)

Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition

Journal of hematology and oncology, 2013-04, Vol.6 (1), p.31-31, Article 31

2013

Volltextzugriff (PDF)

PB1 Domain-Dependent Signaling Complex Is Required for Extracellular Signal-Regulated Kinase 5 Activation

Molecular and Cellular Biology, 2006-03, Vol.26 (6), p.2065-2079

2006

Volltextzugriff (PDF)

MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability

Oncogene, 2005-01, Vol.24 (5), p.801-809

2005

Volltextzugriff (PDF)

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational new drugs, 2013-08, Vol.31 (4), p.833-844

2013

Volltextzugriff (PDF)

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

The Journal of immunology (1950), 2019-05, Vol.202 (10), p.2945-2956

2019

Volltextzugriff (PDF)

Stromal-Based Signatures for the Classification of Gastric Cancer

Cancer research (Chicago, Ill.), 2016-05, Vol.76 (9), p.2573-2586

2016

Volltextzugriff (PDF)

Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα

The EMBO journal, 2001-12, Vol.20 (23), p.6805-6815

2001

Volltextzugriff (PDF)

Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma

Anticancer research, 2016-06, Vol.36 (6), p.2683-2696

2016

Volltextzugriff (PDF)

High-content multiplexed tissue imaging and quantification for cancer drug discovery

Drug discovery today, 2013-06, Vol.18 (11-12), p.510-522

2013

Volltextzugriff (PDF)

Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes

Molecular cancer research, 2012-06, Vol.10 (6), p.739-749

2012

Volltextzugriff (PDF)

Wiring diagrams of MAPK regulation by MEKK1, 2, and 3

Biochemistry and cell biology, 2004-12, Vol.82 (6), p.658

2004

Volltextzugriff (PDF)

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD1-02-PD1-02

2020

Volltextzugriff (PDF)

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-129-LB-129

2018

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(70)
Dissertationen
(1)

Sprache

Englisch
(71)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(29)
Humans
(27)
Animals
(21)
Mice
(16)
Oncology
(16)
Biochemistry & Molecular Biology
(12)
Female
(10)
Kinases
(10)
Cell Biology
(9)
Neovascularization, Pathologic - Drug Therapy
(7)
Xenograft Model Antitumor Assays
(7)
Angiogenesis
(6)
Biological And Medical Sciences
(6)
Cell Line, Tumor
(6)
Immunotherapy
(6)
Phosphorylation
(6)
Proteins
(6)
Signal Transduction
(6)
Tumors
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents

Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies

Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition

Structural and Evolutionary Division of Phosphotyrosine Binding (PTB) Domains

CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis

Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models

Ablation of MEKK4 Kinase Activity Causes Neurulation and Skeletal Patterning Defects in the Mouse Embryo

Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition

PB1 Domain-Dependent Signaling Complex Is Required for Extracellular Signal-Regulated Kinase 5 Activation

MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Stromal-Based Signatures for the Classification of Gastric Cancer

Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα

Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma

High-content multiplexed tissue imaging and quantification for cancer drug discovery

Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes

Wiring diagrams of MAPK regulation by MEKK1, 2, and 3

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

Suchergebnisse filtern